Last reviewed · How we verify
Oxytocin 400 i.u. — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Oxytocin 400 i.u. (Oxytocin 400 i.u.) — PepTonic Medical AB.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Oxytocin 400 i.u. TARGET | Oxytocin 400 i.u. | PepTonic Medical AB | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Oxytocin 400 i.u. CI watch — RSS
- Oxytocin 400 i.u. CI watch — Atom
- Oxytocin 400 i.u. CI watch — JSON
- Oxytocin 400 i.u. alone — RSS
Cite this brief
Drug Landscape (2026). Oxytocin 400 i.u. — Competitive Intelligence Brief. https://druglandscape.com/ci/oxytocin-400-i-u. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab